文献速递肿瘤 PET/CT

转移性18F-DCFPyL阴性前列腺腺癌且无神经内分泌分化

Metastasized 18F-DCFPyL-Negative Prostatic Adenocarcinoma Without Neuroendocrine Differentiation.
PubMed 文献 · Clin Nucl Med · 2018-01-01

一名76岁男性,初诊前列腺特异性抗原110 ng/mL、Gleason评分3+4=7,接受18F-DCFPyL PET/CT初始分期,原发肿瘤及病理性增大的盆腔淋巴结均无18F-DCFPyL摄取增高,后续淋巴结活检证实为前列腺癌转移。本文报道了无神经内分泌分化的前列腺腺癌出现18F-DCFPyL PET假阴性的情况。

要点

  • 18F-DCFPyL PET/CT可用于前列腺癌显像,但本例原发灶及盆腔转移淋巴结均无摄取增高。
  • 淋巴结活检病理证实为前列腺癌转移,提示18F-DCFPyL PET存在假阴性可能。
  • 既往假阴性报道多见于神经内分泌分化肿瘤,本例腺癌无神经内分泌分化。

核心结论

  • 本文报道了一例无神经内分泌分化的前列腺腺癌出现18F-DCFPyL PET假阴性表现。

研究设计与样本

  • 本文为病例报告,患者为76岁男性,经组织病理学证实为前列腺癌,初始前列腺特异性抗原110 ng/mL,Gleason评分3+4=7。

主要发现

  • 18F-DCFPyL PET/CT显示原发肿瘤及病理性增大的盆腔淋巴结均无18F-DCFPyL摄取增高。
  • 后续淋巴结组织病理学活检证实为前列腺癌转移。

关键数值与推荐

  • 初始前列腺特异性抗原110 ng/mL,Gleason评分3+4=7。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A 76-year-old man with histopathologically proven prostate cancer (initial prostate-specific antigen 110 ng/mL, Gleason 3 + 4 = 7) received F-DCFPyL PET/CT for initial staging. Both the primary tumor and pathologically enlarged pelvic lymph nodes showed no increased F-DCFPyL uptake. Subsequent histopathologic lymph node biopsy revealed prostate cancer metastasis. Prostate-specific membrane antigen tracers, such as F-DCFPyL, are promising radiopharmaceuticals for prostate cancer imaging. False-negative prostate-specific membrane antigen PET/CT findings have been reported earlier for prostate tumors with neuroendocrine differentiation. However, this report presents false-negative F-DCFPyL PET findings of an adenocarcinoma of the prostate without neuroendocrine differentiation.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Broos WAM, Kocken M, van der Zant FM, et al. Metastasized 18F-DCFPyL-Negative Prostatic Adenocarcinoma Without Neuroendocrine Differentiation. Clin Nucl Med. 2018. PMID: 29261618. doi:10.1097/RLU.0000000000001929

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。